Specialty gaining traction
Sun Pharmaceutical Industries’ (Sun) reported Q4FY20 performance was below our estimates due to higher operating costs and forex loss,..
Specialty Portfolio – long road to profitability
* FY20 ended on a weak note with a sharp decline in Q4 margins (-590bpsqoq, 400bps lower than our est.), even as..
* Specialty scale up delayed
Sun’s Q4 EBIDTA/PAT missed expectations on account of higher costs and certain one off expenses. US business (ex Taro) was largely s..
4Q: Miss on profitability due to product mix and COVID-19
Initial signs of uptick in prescription trends in Specialty portfolio
* Post the reduction in prescriptio..
BENGALURU - Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug naf..
The company reported standalone net profit of Rs 1,155.85 crore for the quarter ended March 31, 2020 as compared to Rs 1068.06 crore in the same period last year, registe..
Sun Pharma (SUNPHA)
Buy Sun Pharma Ltd @469.00-471.00 CMP 469.45 Target 478.50 SL 465.60
REC Ltd (RURELE)
Sell REC Ltd..
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel https://t.me/Investment..
Accelya Solutions In Q4 net profit up 32.35% at Rs 24.71 cr
US dollar rises after Fed policy meeting
Rupee rises by 12 paise to Rs 69.05 against dollar
Headwinds recede for Tata Motors, but it is not out of the woods just yet
Infosys signs agreement with U.S. IRS; sees lower tax rate
Crude Oil markets shift focus on the OPEC Meeting By Mr. Prathamesh Mallya, Angel Broking
Daily Market Commentary 14 July 2020 by Mr. Siddhartha Khemka, Motilal Oswal
Market corrects in tandem with global peers by Mr. Sameet Chavan, Angel Broking
Turmeric prices look to trade in the range of 5300-5900 - Kedia Advisory
© Copyright 2017 - investmentguruindia | All Rights Reserved. | Crafted By - Digi Interface